T1	Participants 412 466	patients (n=209 MG, n=96 placebo) with UC in remission
T2	Participants 559 618	who took MG 1.5 g or placebo once-daily for up to 6 months.
T3	Participants 646 727	the percentage of patients who remained relapse-free at month 6/end of treatment.
T4	Participants 886 1046	he percentage of relapse-free patients at month 6/end of treatment was higher with MG than placebo (78.9% vs. 58.3%, P < 0.001) in the intent-to-treat analysis.
